周四盘中，生物制药公司Arcutis Biotherapeutics（股票代码：ARQT）股价大涨6.71%，延续了盘前的上涨势头。这波涨势主要源于公司最新发布的第二季度财报优于市场预期，引发投资者热情。
据Arcutis Biotherapeutics公布的财报显示，截至6月30日的第二季度，公司调整后每股亏损为0.13美元，明显好于分析师平均预期的0.16美元亏损。公司营收达到8150万美元，同比大幅增长164.1%，同样超过了分析师预期的7369万美元。尽管公司仍录得1554万美元的季度亏损，但业绩的显著改善无疑提振了投资者信心。
值得注意的是，华尔街分析师对Arcutis Biotherapeutics保持乐观态度。目前，分析师对该公司股票的平均评级为"买入"，其中7个评级为"强烈买入"或"买入"，1个为"持有"，没有"卖出"或"强烈卖出"评级。分析师给出的12个月目标价中位数为20.00美元，较上一交易日收盘价15.33美元高出约23.4%。这一积极的分析师评级和看好的目标价，也为公司股价上涨提供了支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.